(NASDAQ: ITRM) Iterum Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.48%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.37%.
Iterum Therapeutics's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast ITRM's revenue for 2025 to be $32,160,707, with the lowest ITRM revenue forecast at $32,160,707, and the highest ITRM revenue forecast at $32,160,707. On average, 1 Wall Street analysts forecast ITRM's revenue for 2026 to be $127,605,384, with the lowest ITRM revenue forecast at $127,605,384, and the highest ITRM revenue forecast at $127,605,384.
In 2028, ITRM is forecast to generate $1,053,003,782 in revenue, with the lowest revenue forecast at $1,053,003,782 and the highest revenue forecast at $1,053,003,782.